In addition to our clinical-stage product candidates, we have two preclinical programs that we believe provide the potential for innovative disease-modifying therapies for treating Parkinson’s disease and other neurological disorders.
In our ER-beta program, we have discovered compounds that exhibit anti-inflammatory and neuroprotective properties in preclinical models and may have the ability to slow down the progression of Parkinson's disease. These compounds also may address the symptoms of chronic, inflammatory and neuropathic pain while avoiding the side effects associated with activating ER-alpha receptors. Our initial studies in the ER-beta program have been supported by grants from The Michael J. Fox Foundation and we were awarded another grant from the National Institute of Neurological Disorders and Stroke.
In a second preclinical program, we discovered compounds that selectively activate Nurr1-RXR complexes and promote viability of dopamine-containing neurons. We are conducting studies to examine the effects of these compounds on neuroprotection and neuroregeneration in preclinical models of Parkinson’s disease pursuant to a separate grant from The Michael J. Fox Foundation.back to top